<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04274790</url>
  </required_header>
  <id_info>
    <org_study_id>ET 19-127 FLUORIB</org_study_id>
    <nct_id>NCT04274790</nct_id>
  </id_info>
  <brief_title>Impact of 5-Fluorouracil (5-FU) on Cancer Cells From Liver Metastases of Colon Cancer</brief_title>
  <acronym>FLUORIB</acronym>
  <official_title>Analysis of the Impact of 5-Fluorouracil on the Translational Control and Plasticity of Cancer Cells From Liver Metastases of Colon Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Analyze the dynamics of incorporation of 5-fluorouracil into cancer cell ribosomes from liver
      metastases of patient with metastatic colon cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a monocentric, prospective, non-interventional cohort study in adult patients with
      metastatic colon cancer with hepatics metastasis.

      Tumour samples collected for this study include:

        -  A fragment of the previously operated primary tumor: FFIP block and/or archived frozen
           tumor if available.

        -  A fragment of the liver metastasis(s) performed as part of standard metastasis surgery,
           this fragment will include a tumor area and a healthy area within the margin of
           excision. These samples collected in a fresh state will be analyzed immediately.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>5-FU in ribosome</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Rate of incorporation of 5-fluorouracil into ribosomes of tumor tissues and adjacent healthy tissues before surgery and after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Methylation profile of ribosomal RNAs</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Analyze on a large scale the alterations of the 2'-O-methylation profile of ribosomal RNAs before surgery and after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcriptomic and proteomic profile</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Define a transcriptomic and proteomic profile of the collected samples before surgery and after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific molecular signature</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Combination of the number of 5-fluorouracil molecules incorporated per rRNA molecule, the methylation profile and the transcriptomic profile before surgery and after surgery.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cancer of Colon</condition>
  <condition>Metastasis to Liver</condition>
  <arm_group>
    <arm_group_label>Metastatic colon cancer</arm_group_label>
    <description>Patient with metastatic colon cancer operated on and followed up at the Centre Leon Berard for liver metastasis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Scheduled and planned surgery</intervention_name>
    <description>Collection of tumour samples from samples collected as part of standard patient management. Diagnostic pathological analysis will be a priority. These samples will be taken by experienced staff during the hospital visit scheduled as part of standard care.</description>
    <arm_group_label>Metastatic colon cancer</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  A fragment of the previously operated primary tumor: block and/or archived frozen tumor
           if available.

        -  A fragment of the liver metastasis.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with metastatic colon cancer in the hepatic phase.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with metastatic colon cancer operated on and followed up at the Centre Leon
             Berard for liver metastasis.

          -  Patient affiliated to social security

        Exclusion Criteria:

          -  Other pathologies that may interfere with biological evaluation, in particular known
             hepatic cirrhosis, whatever its origin, other liver overload diseases
             (hemochromatosis, Wilson's disease), but excluding steatosis (which can be
             chemo-induced).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe CASSIER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe CASSIER, MD</last_name>
    <phone>+33(0)4 26 55 68 35</phone>
    <email>philippe.cassier@lyon.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Philippe CASSIER, MD</last_name>
      <email>philippe.cassier@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>February 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

